Journal of Clinical Oncology
Articles in this Issue
Receipt of poly(ADP) ribose polymerase inhibitors (PARPi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring <i>BRCA1/2</i> alterations.
108 Background: PARPi are approved for the treatment of pts with mCRPC either as single agents or as a combination with an androgen receptor pathway inhib...
Concurrent pembrozulimab and radiation treatments in the management of locally advanced bladder cancer in cisplatin-ineligible patients.
817 Background: Pembrolizumab (P) is commonly used to treat cisplatin-ineligible patients with locally advanced bladder cancer. We previously reported a p...
Cabozantinib in patients (pts) with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC): Results of the multicenter CABRAMET phase II trial (NCT03967522).
533 Background: Despite dramatic progress in metastatic RCC treatments, pts with BM remain with poor outcome and were mostly excluded from clinical trials...
Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis.
550 Background: Non-clear cell renal cell carcinoma (nccRCC) represents a genetically and histologically diverse subset of renal cancers, accounting for 1...
A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men.
35 Background: PREP was initiated in Ontario to provide access and characterize performance of PSMA PET CT among men with recurrent prostate cancer after...
Time from medication order to administration of cabazitaxel (C) vs. lutetium Lu-177 vipivotide tetraxetan (Lu) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
109 Background: C and Lu are associated with overall survival benefit and approved for pts with mCRPC after prior treatmen...
Real-world discontinuation and efficacy data of abiraterone acetate/prednisone (AAP) plus androgen deprivation therapy and radiotherapy in localized prostate cancer.
367 Background: Data from STAMPEDE trial confirmed Overall survival benefit for patients with high-risk localized or locally advanced prostate cancer trea...
Prognosis in metastatic renal cell cancer (mRCC) with major venous involvement (MVI): A population-based study.
454 Background: Limited data exist on outcomes in mRCC patients with major venous involvement (MVI). Assessment of impact of a given variable on prognosis...
Interim analysis of the “shutter speed” MRI model to detect clinically significant prostate cancer.
339 Background: Prostate cancer (PCa) MRI can fail to identify high-grade lesions, and mis-grade lesions, up to 30% of the time. Objective imaging techniq...
INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).
TPS610 Background: The PD-1 inhibitor pembro is approved as monotherapy for the adjuvant treatment of patients with RCC at...
Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).
20 Background: Clinical features of people with mHSPC may affect their outcomes from the addition of ARPIs to androgen deprivation therapy (ADT). The STOP...
Evaluation of post radiotherapy PSA as a prognostic and predictive biomarker in high risk prostate cancer: A secondary analysis of RTOG 0521.
384 Background: RTOG 0521 was a randomized trial of radiotherapy (RT) and 24 months of androgen deprivation (ADT) with and without docetaxel (D) in high r...
Primary sarcomas of urinary bladder: A SEER analysis.
878 Background: Primary bladder sarcoma (PBS) is a rare entity. In this study, we analyzed demographics, clinical characteristics, and survival outcomes o...
Mortality risk in clinical T1a renal cell carcinoma (RCC) with synchronous metastasis (SM): A comparative analysis of National Cancer Database (NCDB).
513 Background: The incidence of RCC has been rising, largely due to increased incidental detection from widespread imaging. Although SM with a primary re...
Treatment patterns and clinical outcomes in patients with metastatic urothelial carcinoma in England: A retrospective observational study.
740 Background: In England, platinum-based chemotherapy with or without an immune checkpoint inhibitor is the standard-of-care for mUC patients. However,...
Automated classification of treatment state of patients with prostate cancer from structured medical record data to help enhance care.
427 Background: The number of US prostate cancer (PCa) cases is projected to expand exponentially while the oncology workforce stagnates. The increase in...
A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial.
312 Background: Men on active surveillance for prostate cancer are extremely interested in dietary changes or supplements to prevent progression of their...
Ethnic disparities in clinical trials for FDA-approved drugs in urothelial cancer: An analysis in the post-COVID-19 era (2020-2024).
677 Background: Ethnic and racial disparities in oncology clinical trial participation continue to pose significant challenges. Despite initiatives by the...
Associations between protein biomarkers and adverse pathologic features in MRI-mapped prostate cancers: An interim analysis.
405 Background: While standard mpMRI has shown benefit in increasing detection of clinically significant prostate cancer, it is limited in its ability to...
Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic papillary renal cell carcinoma: A GUARDIANS project.
496 Background: Papillary (pRCC) renal cell carcinoma is a rare cancer. We evaluated real-world treatment outcomes of 1st line treatment in these cohorts...
Real-world use of bone-modifying agents (BMA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the US.
95 Background: Most pts with prostate cancer with bone metastasis experience symptomatic skeletal events (SSEs) [PMID: 23884473], leading to increased mor...
Phase 1/2 OMAHA-01A substudy of oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies for metastatic castration-resistant prostate cancer (mCRPC).
TPS300 Background: Current treatments for mCRPC are associated with hormone dependence and the development of resistance. Therapeutic agents with novel me...
Clinical experience with EMACO chemotherapy in male choriocarcinoma: A single-center study.
640 Background: Choriocarcinoma is an aggressive subtype of germ cell tumor that frequently metastasizes and progresses rapidly. In gestational trophoblas...
Role of liquid biopsy in the detection of homologous recombination repair gene mutations (HRRm) in metastatic prostate cancer (mPC).
51 Background: The treatment landscape of mPC is rapidly evolving to include more precision therapies for patients with actionable genomic alterations. Sp...
Modified transurethral resection of bladder tumors: A comparison study of chemotherapy-enhanced endoscopic submucosal en bloc dissection versus conventional resection.
721 Background: High recurrence rates plague patients with nonmuscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumors (...